High U.S. drug tariffs could rattle Asian supply chains, Barclays warns

Published 09/07/2025, 07:40
© Reuters

Investing.com -- President Donald Trump has said U.S. pharmaceutical tariffs will be set at a “very, very high rate, like 200%.”

Strategists at Barclays (LON:BARC) estimate that a rate as high as 200% could significantly disrupt Asian supply chains, with Singapore likely to face the sharpest impact due to its central role in global pharmaceutical production and trade.

Barclays estimates that 2.3% of Singapore’s value-added (VA) is exposed to such a tariff—by far the highest in Emerging Asia.

“A 200% pharmaceutical tariff could potentially result in Singapore experiencing one of the largest VA-weighted U.S. tariff increases globally,” the strategists led by Brian Tan wrote.

That would lift Singapore’s VA-weighted U.S. tariff rate by 4.5 percentage points, from a current level of just 0.4%. Singapore is already in talks with the U.S. to secure tariff concessions for pharmaceutical and semiconductor exports.

India, Korea, and Malaysia would also be affected, though to a lesser degree, with estimated VA-weighted increases of 0.7pp, 0.4pp, and 0.3pp, respectively. Barclays notes these figures capture both direct and indirect exposure through complex global supply chains.

Trump has indicated a grace period of at least a year before pharmaceutical tariffs are enforced.

“We’ll give them a certain period of time to get their act together,” he said.

By contrast, a separate 50% copper tariff—also outlined by the Trump administration—would have limited consequences for Emerging Asia. The biggest impact would fall on top copper exporters like Chile and Peru, strategists said.

The bank’s analysis uses OECD trade in value-added data to capture both direct and indirect exposure to U.S. tariffs through global supply chains.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.